Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Location: United States, New York
Employees: 51-200
Total raised: $105M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.05.2020 | Series A | $20M | - |
| 15.12.2019 | Series C | $85M | - |
Mentions in press and media 10
| Date | Title | Description |
| 21.08.2026 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) Fri, Aug 21, 2026 07:30 CET Report this content Lund, Sweden August 21, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office i... |
| 26.03.2025 | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened... |
| 27.04.2022 | Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer | Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for ... |
| 10.08.2021 | Digital health news, funding roundup in the prior week; August 9 | PepGen raised $112.5M; Lucid Lane landed $16M; Kensho Health secured $3.5M; DynamiCare Health picks T-knife Therapeutics: T-knife Therapeutics is a Berlin-based, pre-clinical-stage biopharmaceutical company developing tumor-specific T cell ... |
| 02.08.2021 | Zentalis Pharmaceuticals : Zentera Therapeutics Announces Closing of $75 Million Series B Financing | SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of a $75 million Series B financing. Foundin... |
| 21.05.2020 | Zentalis Pharmaceuticals Raises $20M in Series A Financing | Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, closed a $20m Series A financi... |
| 02.04.2020 | Zentalis Pharmaceuticals had a successful IPO, raising $165M in its stock market debut. The company lists San Diego as the base for its scientific office. | - |
| 15.12.2019 | Zentalis Receives $85M in Funding To Target Cancer | Cancer drug developer Zentalis Pharmaceuticals recently surfaced with an $85 million round... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Subscriber-only digital con... |
| 09.12.2019 | Zentalis Pharmaceuticals Raises $85 Million in Oversubscribed Series C | NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, t... |
| 09.12.2019 | Zentalis Pharmaceuticals Raises $85M in Series C | NEW YORK, NY, Zentalis Pharmaceuticals announced the completion of an $85 million Series C financing. >> Click here for more funding data on Zentalis Pharmaceuticals >> To export Zentalis Pharmaceuticals funding data to PDF ... |